Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;12(10):e70022.
doi: 10.1002/iid3.70022.

Biomarkers for systemic lupus erythematosus: A scoping review

Su-Jie Zhang  1 , Rui-Yang Xu  1 , Long-Li Kang  1
Affiliations

Biomarkers for systemic lupus erythematosus: A scoping review

Su-Jie Zhang et al. Immun Inflamm Dis. 2024 Oct.

Abstract

Background: In recent years, newly discovered potential biomarkers have great research potential in the diagnosis, disease activity prediction, and treatment of systemic lupus erythematosus (SLE).

Objective: In this study, a scoping review of potential biomarkers for SLE over several years has identified the extent to which studies on biomarkers for SLE have been conducted, the specificity, sensitivity, and diagnostic value of potential biomarkers of SLE, the research potential of these biomarkers in disease diagnosis, and activity detection is discussed.

Methods: In PubMed and Google Scholar databases, "SLE," "biomarkers," "predictor," "autoimmune diseases," "lupus nephritis," "neuropsychiatric SLE," "diagnosis," "monitoring," and "disease activity" were used as keywords to systematically search for SLE molecular biomarkers published from 2020 to 2024. Analyze and summarize the literature that can guide the article.

Conclusions: Recent findings suggest that some potential biomarkers may have clinical application prospects. However, to date, many of these biomarkers have not been subjected to repeated clinical validation. And no single biomarker has sufficient sensitivity and specificity for SLE. It is not scientific to choose only one or several biomarkers to judge the complex disease of SLE. It may be a good direction to carry out a meta-analysis of various biomarkers to find SLE biomarkers suitable for clinical use, or to evaluate SLE by combining multiple biomarkers through mathematical models. At the same time, advanced computational methods are needed to analyze large data sets and discover new biomarkers, and strive to find biomarkers that are sensitive and specific enough to SLE and can be used in clinical practice, rather than only staying in experimental research and data analysis.

Keywords: biomarkers; diagnosis; disease activity; lupus nephritis; monitoring; neuropsychiatric in SLE; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Liu Z, Davidson A. Taming lupus—a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18(6):871‐882. 10.1038/nm.2752 - DOI - PMC - PubMed
    1. Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716‐730. 10.1038/nrrheum.2016.186 - DOI - PubMed
    1. Gergianaki I, Fanouriakis A, Repa A, et al. Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community‐based lupus registry of Crete, Greece. Ann Rheum Dis. 2017;76(12):1992‐2000. 10.1136/annrheumdis-2017-211206 - DOI - PubMed
    1. Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277‐A287. 10.1016/j.autrev.2009.12.008 - DOI - PubMed
    1. Anastasiou C, Trupin L, Glidden DV, et al. Mortality among hospitalized individuals with systemic lupus erythematosus in the US between 2006 and 2016. Arthritis Care Res. 2021;73(10):1444‐1450. 10.1002/acr.24356 - DOI - PMC - PubMed

Publication types

MeSH terms